A group of Senate Democrats has agreed to re-open the government, at least until January, without receiving a guarantee that their key demand of extending healthcare insurance subsidies will be met by GOP lawmakers.
That breakthrough was secured after the Senate held a rare session on Sunday to chart a way out of the longest ever government shutdown in the history of the country. During that session, a number of centrist Democrats negotiated with GOP Senators and the Democrats promised to vote in favor of re-opening the government on condition that they were given a promise that the chamber would vote on extending the healthcare subsidies that are slated to expire in December.
The talks were led by Sen. Angus King. He revealed that according to the group he led, the current shutdown had gone on for way too long, and now was the time to end it. While speaking to the press, he said it appeared there would be enough votes to see the bill through.
The package in question contains language that would provide funding to the government until January and ensure continuity for other activities, such as the legislative body and food aid for the entire 2026. This particular package would have to go to the House for consideration before being sent to the president for his signature. This process could take days to be completed.
On his return to the White House after spending his weekend in Florida, Trump boasted that chances are high that the government would be re-opened soon.
However, things aren’t as clear-cut as the brokers of this deal want them to be. Many Democrats are unhappy with the contents of the package. For example, Sen. Richard Blumenthal from Connecticut said he can’t support a vague promise with an unclear timeline. However, he concedes that enough Democrats could support the deal and agree to pass it.
The CR bill (continuing resolution) aims to provide funding to government at levels that existed before the current shutdown started. So far, the Democrats supporting it include Blumenthal, Tim Kaine, Maggie Hassan and Jeanne Shaheen. One more Democrat would see the measure secure the needed support for its passage, assuming all Republicans vote in favor.
Chuck Schumer, the Minority Leader in Senate, says the deal is unacceptable and many of his colleagues in the chamber regard the package as something betraying millions of citizens that have been counting on the Democrats to fight for them. It remains to be seen whether this “capitulation”, as many call the package, will sail through.
Players in the healthcare sector, such as Astiva Health, are likely to take a keen interest in the next vote of the Senate to see what decision is reached. The stakes are high, and the country will be watching with bated breath.
NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
